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Abstract
Background: Colorectal cancer (CRC) is one of the most common malignancies in the world. microRNA-140-5p
(miR-140) has been shown to be involved in cartilage development and osteoarthritis (OA) pathogenesis. Some
contradictions still exist concerning the role of miR-140 in tumor progression and metastasis, and the underlying
mechanism is uncertain.
Methods: Immunohistochemistry was performed to determine the expressions of ADAMTS5 and IGFBP5 in CRC
tissues. Human CRC cell lines HCT116 and RKO were transfected with miR-140 mimic, inhibitor, or small interfering
RNA (siRNA) against ADAMTS5 or IGFBP5, respectively, using oligofectamine or lipofectamine 2000. Scratch-wound
assay and transwell migration and invasion assays were used to evaluate the effects of miR-140 on the capabilities
of migration and invasion. The levels of miR-140 and ADAMTS5 and IGFBP5 mRNA were measured by quantitative
real-time polymerase chain reaction (qRT-PCR). Western blot was performed to examine the expression of
ADAMTS5 and IGFBP5 proteins.
Results: miR-140 was significantly reduced, whereas ADAMTS5 and IGFBP5 were upregulated, in the human CRC
tissues compared to the corresponding normal colorectal mucosa. miR-140 downregulation and ADAMTS5 or
IGFBP5 overexpression were associated with the advanced TNM stage and distant metastasis of CRC. There was
a reverse correlation between miR-140 levels and ADAMTS5 and IGFBP5 expression in CRC tissues. ADAMTS5 and
IGFBP5 were downregulated by miR-140 at both the protein and mRNA levels in the CRC cell lines. The gain-of-
and loss-of-function studies showed that miR-140 inhibited CRC cell migratory and invasive capacities at least
partially via downregulating the expression of ADAMTS5 and IGFBP5.
Conclusions: These findings suggest that miR-140 suppresses CRC progression and metastasis, possibly through
downregulating ADAMTS5 and IGFBP5. miR-140 might be a potential therapeutic candidate for the treatment of CRC.
Keywords: Colorectal cancer, microRNA-140-5p, ADAMTS5, IGFBP5, Invasion, Metastasis
* Correspondence: songbo9177@163.com; yr0806@hotmail.com
†Equal contributors
1Department of Pathology, Dalian Medical University, Dalian 116044, People’s
Republic of China
2Teaching Laboratory of Morphology, Dalian Medical University, No. 9 West
Section, Lvshun South Road, Dalian 116044, People’s Republic of China
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Yu et al. Stem Cell Research & Therapy  (2016) 7:180 
DOI 10.1186/s13287-016-0438-5
Background
Colorectal cancer (CRC) is one of the most common
malignancies and the second most common cause of
cancer deaths worldwide [1, 2]. Surgery with or without
adjuvant radiation and chemotherapy treatments based
on tumor stages have been recommended according to
current guidelines. However, there are still patients with
early surgery suffering from metastases, especially liver
metastases, which can finally result in death [3]. Like
other solid cancers, the development of CRC is a multi-
step progression involving the activation of oncogenes
and inactivation of tumor suppressor genes, which will
affect all aspects of tumorigenicity of CRC, such as cell
proliferation, apoptosis, invasion, and metastasis [4]. Be-
cause of the disease complexity, the specific molecular
genetic and epigenetic alterations of CRC remain largely
unknown.
MicroRNAs (miRNAs) are small (19–25 nucleotides),
noncoding, regulatory RNAs that can negatively regulate
gene expression by complementary base pairing with the
3′-untranslated region (UTR) of target messenger RNAs
(mRNAs), leading to their degradation or repression of
mRNA translation [5, 6]. Abnormal expression of miR-
NAs is suggested to be associated with various human
disorders, including cancer, indicating that they play a
critical role in the molecular mechanism of cancer
pathogenesis and progression [7].
The gene encoding microRNA-140-5p (miR-140) is lo-
cated in chromosome 16. It was first found as a
cartilage-specific expression microRNA. Wienholds et al.
[8] and Tuddenham et al. [9] reported that miR-140 was
specifically expressed in cartilage tissues of zebrafish and
mouse embryos, and later its downregulation was shown
to play a critical role in the pathogenesis of osteoarthritis
(OA) [10–12]. Importantly, several recent studies have
revealed the functions of miR-140 in tumorigenesis. The
results from our group showed that ectopic expression
of miR-140 in human osteosarcoma and CRC cells can
induce cell cycle arrest and inhibit cell proliferation, in
part through the suppression of histone deacetylase 4
(HDAC4) [13]. In hepatocellular carcinoma (HCC), miR-
140 was found to target TGFBRI and FGF9, and its overex-
pression could suppress HCC growth and metastasis [14].
In non-small cell lung cancer (NSCLC), miR-140 can tar-
get IGF1R and monocyte to macrophage differentiation-
associated (MMD) to inhibit tumor growth and metastasis
[15]. miR-140 inhibited esophageal cancer cell invasion by
targeting slug and the subsequent epithelial-mesenchymal
transition (EMT) process [16]. Additionally, several studies
indicated that downregulation of miR-140 can promote
cancer stem cell (CSC) formation in breast cancer and
CRC [17–21]. However, some contradictions still exist
concerning the role of miR-140 in tumor progression.
Malzkorn et al. [22] reported that miR-140 is one of the
increased microRNA candidates in glioma progression
from grade II to grade IV. Güllü et al. [23] also found that
miR-140 is overexpressed in the invasive ductal breast can-
cer tissues and lymph node-positive samples. Based on the
above studies, we intend to investigate the impact and
mechanism of miR-140 on CRC progression.
A disintegrin and metalloproteinase with thrombos-
pondin motifs (ADAMTS) family is a type of newly dis-
covered, zinc-dependent secreted proteinase consisting
of 19 members that share the metalloproteinase domain
with matrix metalloproteinases (MMPs) [24]. Among
ADAMTSs, ADAMTS5 (aggrecanase-2) is well known
for its importance in cartilage destruction [24]. Recently,
increasing evidence suggests that ADAMTS5 is involved
in cancer development and progression. Nakada et al.
[25] reported that ADAMTS5 is upregulated in human
glioblastoma compared to the normal brain tissues and
its overexpression can enhance the invasive capacity of
glioblastoma cells through matrigel which contains bre-
vican, a substrate for ADAMTS5. Another study showed
that higher mRNA expression of ADAMTS5 is found in
the metastatic foci of head and neck cancer as compared
to their corresponding primary tumors as well as normal
tissues [26]. Filou et al. [27] reported that ADAMTS5 is
the main type of aggrecanase expressed in the laryngeal
squamous cell carcinoma (LSCC) and presents a stage-
related increase. A more recent study reported that miR-
144/451 inhibits breast cancer and head and neck
squamous cell carcinoma (HNSCC) metastasis by target-
ing ADAMTS5 and ADAM10, and the overexpression
of these two proteins being significantly associated with
lymph node metastasis and pathological grade [28].
Insulin-like growth factor (IGF)-binding proteins
(IGFBPs) are important regulators of the IGF signaling
pathway which consists of six members [29]. IGFBP5,
the most conserved member of the IGFBPs in all verte-
brates, has been found to play a role not only in the
physical processes, such as cell growth, death, and motil-
ity, but also in the pathologic processes such as cancer
development and metastasis [30]. IGFBP5 promotes pros-
tate cancer growth in vitro and in vivo [31–33]. The
plasma levels of IGFBP5 are 1.5-fold higher in breast
cancer-bearing mice than in nontumor-bearing mice and
are positively correlated with the tumor size [34]. In a rat
colon cancer model, IGFBP5 is among the most upregu-
lated gene by microarray gene expression analysis [35].
Hao et al. [36] reported that the expression of IGFBP5 is
increased in breast cancers with axillary lymph node in-
volvement and lymph node metastatic tissues compared
with primary breast cancer samples. Wang et al. [37] also
found that IGFBP5 is more highly expressed in T1 invasive
breast cancer than in normal breast epithelium. Moreover,
T1N1 breast cancers are more likely to have moderate and
strong positive staining for IGFBP5 than T1N0 cancers.
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These data suggest that ADAMTS5 and IGFBP5 may
promote the tumorigenesis and cancer progression.
Very interestingly, Miyaki et al. [10] and Tardif et al.
[38] have experimentally confirmed that ADAMTS5
and IGFBP5 are the direct targets of miR-140 in
HEK293T cells and human OA chondrocytes, respect-
ively. Our previous study has shown that miR-140 in-
hibits human osteosarcoma and CRC cell growth and is
also involved in the chemoresistance to methotrexate
and 5-fluorouracil (5-FU) [13]. In the current study, we
investigated the suppressive role of miR-140 in CRC
progression and the correlation with downregulating
ADAMTS5 and IGFBP5.
Methods
Cell culture and reagents
The human CRC cell lines, HCT116 and RKO, were
purchased from the Cell Bank of the Chinese Academy
of Sciences, Shanghai, China. HCT116 cells were main-
tained in McCoy’s 5A medium (Gibco) and RKO cells
were cultured in MEM medium (Gibco) containing 10%
fetal bovine serum (FBS; Gibco) in a 5% CO2 container
at 37 °C.
Clinical specimens
Sixty CRC patients admitted to the First Affiliated Hos-
pital of Dalian Medical University, Dalian, China, were
enrolled in this study. The use of human tissue samples
was in accordance with relevant guidelines and regula-
tions, and the experimental protocols were approved by
the Medical Ethics Committee of the First Affiliated
Hospital of Dalian Medical University. All patients have
complete clinicopathological data. The adjacent normal
colorectal tissue of each patient within at least 5 cm of
the tumor margin [39] was also collected as the negative
control. All patients provided written informed consent
prior to participation in this study. The CRC specimens
were histologically examined by hematoxylin and eosin
(H&E) staining.
Transfections of the miRNA mimics and siRNAs specific
for ADAMTS5 and IGFBP5
HCT116 and RKO cells (3 × 105 per well) were plated in
six-well plates and then transfected with 100 nM of either
miR-140 mimic or negative miRNA (Invitrogen) after 24 h
with oligofectamine (Invitrogen) according to the ma-
nufacturer’s protocols, respectively. Small-interfering
RNAs (siRNAs) specific for ADAMTS5 or IGFBP5 (siA-
DAMTS5 or siIGFBP5) from Invitrogen were transfected
with oligofectamine at a final concentration of 100 nM in
Opti-MEM I Reduced Serum Medium (Life Technology)
according to the manufacturer’s instructions. The trans-
fected cells were harvested for RNA isolation and protein
extraction at 24 h and 48 h after transfection, respectively.
miR-140 knockdown
To knock down the endogenous miR-140, HCT116 and
RKO cells were transfected with 100 nM of scrambled
miRNA inhibitor or miR-140 inhibitor by lipofectamine
2000 (Invitrogen) in six-well plates (3 × 105 cells/well),
respectively. The miRNA inhibitors were purchased
from Invitrogen. Co-transfections of miR-140 inhibitor
and siADAMTS5 or siIGFBP5 were the negative control.
The transfected cells were harvested for protein extrac-
tion at 72 h post-transfection.
Scratch-wound assay
A scratch-wound assay was performed to evaluate the
effect of miR-140 on CRC cell migration. The CRC cells
(3 × 105 cells/well) in six-well plates were transfected with
miRNAs, miRNA inhibitors, or siRNAs and cultured until
reaching confluence. A 10 μl pipette tip was used to
scrape the monolayer cells for generating a scratch wound.
The wounded surface was washed with 1 × phosphate-
buffered saline (PBS) to remove the cell debris and there-
after cultured in the serum-free medium. At 72 h after
scrape, the wound closures were photographed with a BZ-
8100 microscope (Keyence, Japan).
Transwell migration and invasion assays
For the transwell invasion assay, 60 μl of matrigel was
diluted with precooled serum-free medium in 1:4 ratios
and was added to the bottom of the transwell chamber
and incubated for 1 h at 37 °C. The parental and trans-
fected cells were resuspended at the density of 1 × 106
cells/ml after starvation for 24 h, then 200 μl of cell sus-
pension (2 × 105 cells) were seeded into the upper cham-
bers (24-well insert; pore size 8 μm), while medium
supplemented with 10% FBS (600 μl) was placed in the
lower chamber. After incubation at 37 °C for 24 h, cells
on the top side of the inserts were removed gently with
a cotton swab. The inserts were then fixed by 4% metha-
nol for 15 min and stained with 0.1% crystal violet for
15 min. The average migratory cells were counted by
randomly choosing five fields each time under the
microscope. The experiments were repeated three times.
For the transwell migration assay, the remaining
protocol was the same as the transwell invasion assay
except for the pre-coat of the matrigel in the inserts.
RNA extraction
Total RNA, including miRNA, were isolated from the
CRC cells with or without transfection and fresh frozen
CRC tissues using TRIzol reagent (Invitrogen) according
to the manufacturer’s instructions.
For human CRC, formalin-fixed, paraffin-embedded
(FFPE) specimens, approximately 0.005 g for each sample,
were extracted. These samples were deparaffinized with
xylene, hydrated by ethanol, and digested with proteinase
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K. Total RNA was isolated using the High Pure RNA Par-
affin Kit (Roche, Germany) according to the manufac-
turer’s instructions.
Quantitative RT-PCR
For quantitative real-time polymerase chain reaction
(qRT-PCR) analysis of miRNA, cDNA was synthesized
using the TaqMan microRNA Reverse Transcription Kit
(Life Technologies). qRT-PCR analysis was performed
on an Agilent MX3000P instrument. The primers for
miR-140 and endogenous control RNU6B were pur-
chased from Ambion. The gene expression (ΔCT) values
of miRNA from each sample were calculated by normal-
izing to RNU6B, and relative quantitation (RQ) values
were plotted.
For qRT-PCR analysis of mRNA expression, cDNA
was synthesized using the PrimeScript RT Reagent Kit
with gDNA Eraser (TaKaRa, Dalian, China). The qRT-
PCR amplification for mRNA was performed with SYBR
Premix Ex Taq II (TaKaRa) on an Agilent MX3000P in-
strument. The gene expression (ΔCT) values of mRNA
from each sample were calculated by normalizing to
GAPDH, and RQ values were plotted. Primers were used
as follows:




IGFBP5: (forward) 5′- GGAGGAGCCGAGAACAC
TG -3′




Protein extraction and Western blot
The parental and transfected cells were washed with
prechilled PBS and lysed in 1 × RIPA buffer (Sigma, St.
Louis). The protein concentration was measured by the
Bradford method with BSA (Sigma) as the standard.
Equal amounts of protein extract (50 μg) were dena-
tured with 8–10% SDS-PAGE, transferred to PVDF
membranes (Millipore), and blocked with 5% non-fat
milk in TBST (0.1 M, pH 7.4). Protein abundance of
GAPDH (1:500; Abgent) served as a control for protein
loading. Each sample was treated with rabbit polyclonal
anti-ADAMTS5 (1:250; Abcam) or mouse monoclonal
anti-IGFBP5 (1:250; Abcam) primary antibodies at 4 °C
overnight. Membranes were incubated with secondary
antibodies, HRP-conjugated rabbit/mouse anti-IgG (LI-
COR Biosciences), diluted at 1:16,000 in TBST, for 2 h at
room temperature. Protein bands were detected by the
Odyssey infrared imaging system (LI-COR Biosciences).
Immunohistochemistry analysis
CRC and normal colorectal tissues were sectioned into 4-
μm thickness slides and were incubated with rabbit
polyclonal anti-ADAMTS5 (1:50; Abcam) or mouse
monoclonal anti-IGFBP5 (1:100; Abcam) overnight at 4 °C
in a humidified container. Detection was determined by a
Non-biotin Horseradish Peroxidase Detection System and
DAB substrate (Dako).
All samples were observed by two pathologists. If there
was a disagreement, the observers would re-examine and
reach a consensus. For scoring expression of antibodies,
both the intensity and extent of immunopositivity were
considered. The dominant staining intensity in tumors
was scored as follows: 0 = negative, 1 = weak, 2 =moder-
ate, and 3 = strong. The extent of positive staining tumor
cells was scored as follows: <25% = 1, 25–50% = 2,
51–75% = 3, and >75% = 4. The final score was deter-
mined by multiplying the intensity and the extent
positivity scores, which yielded a range from 0 to 12.
The mean score from each individual was calculated in
tumor cells. The positive expression for markers was
scored as follows: >1, IGFBP5 and >2, ADAMTS5. The
positive expression of ADAMTS5 and IGFBP5 was found
mainly on the cytoplasm of cells. They were presented as
a brown granular material.
Statistical analysis
Statistical analysis was performed using the SPSS soft-
ware, version 11.0. The results were expressed as the
mean ± standard deviation. Student’s t test was used to
determine the significance of two groups. Two matched
clinical sample groups were analyzed by paired t test and
two unpaired groups were analyzed by unpaired t test.
One-way analysis of variance (ANOVA) followed by a
Bonferroni-Dunn test was used to compare more than
two groups. The correlation between miR-140 and
ADAMTS5 or IGFBP5 expression was calculated using
Spearman’s correlation coefficient. The chi-square test
was used to assess the associations among the positive
staining of ADAMTS5 or IGFBP5 and clinicopathologi-
cal indices. P < 0.05 was considered statistically
significant.
Results
miR-140 expression is reduced in the CRC specimens, and
its downregulation is associated with the tumor stage
and metastasis
To determine the role of miR-140 in CRC development
and progression, we evaluated the expressions of miR-
140 in 60 paired CRC specimens and the corresponding
normal colorectal tissues using qRT-PCR analysis. We
found that miR-140 expression was significantly de-
creased in the CRC tissues compared with the normal
controls (P = 0.037, Fig. 1).
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All cases were then divided into a miR-140 low-
expression group (n = 28) and a high-expression group
(n = 32) using the median value as the cut off. The cor-
relation between miR-140 expression and clinicopatho-
logical parameters was shown in Table 1. Our results
indicated that miR-140 was negatively correlated with
tumor stage (P = 0.045) and metastasis (P = 0.031). No
significance was found for age, gender, or histological
differentiation. These findings suggested that miR-140
may play a critical role in CRC development and
progression.
ADAMTS5 and IGFBP5 are downregulated by miR-140 in
HCT116 and RKO cells
Bioinformatics analysis using the computational pro-
grams (microrna.org, targetscan.org, and pictar.mdc-ber-
lin.de) has shown that the 3′-UTR of ADAMTS5 or
IGFBP5 mRNA contains the putative binding sites of
miR-140 (Fig. 2a). The later studies performed by Miyaki
et al. [10] and Tardif et al. [38] have experimentally iden-
tified that ADAMTS5 and IGFBP5 are the direct targets
of miR-140 in HEK293T cells or human OA chondro-
cytes. To further confirm that the expressions of
ADAMTS5 and IGFBP5 are indeed regulated by miR-
140 in CRC cells, we transiently transfected either miR-
140 mimic or negative miRNA into HCT116 or RKO
cells. The successful transfection of miR-140 was verified
by qRT-PCR (Fig. 2b). The expressions of ADAMTS5
and IGFBP5 at both protein and mRNA levels were
quantified by Western blot and qRT-PCR, respectively.
We found that miR-140 inhibited the protein expressions
(Fig. 2c) and decreased the mRNA levels of ADAMTS5
and IGFBP5 (Fig. 2d) in both HCT116 and RKO cells
compared to the negative controls. Knockdown of
ADAMTS5 and IGFBP5 by siRNAs were used as the posi-
tive control. These data indicated that ADAMTS5 and
IGFBP5 expressions are regulated by miR-140 at the post-
transcriptional level in the CRC cells, and this is consistent
with the previous results [10, 38].
Next, we performed loss-of-function analysis to fur-
ther confirm the regulation of ADAMTS5 and IGFBP5
by miR-140. The endogenous miR-140 was knocked
down with inhibitor in HCT116 and RKO cells using
lipofectamine 2000. To more accurately verify the regu-
lation between miR-140 and ADAMTS5 or IGFBP5, we
co-transfected miR-140 inhibitor and siRNA against
ADAMTS5 or IGFBP5, respectively, into the CRC cells
and considered it as a negative control. Meanwhile, li-
pofectamine 2000 alone and scrambled oligonucleotide
of miRNA inhibitor were used as the negative control.
We found that endogenous miR-140 knockdown can
restore the expression of ADAMTS5 or IGFBP5 when
compared to the negative controls using Western
blot (Fig. 2e). All these results indicated that
ADAMTS5 and IGFBP5 are downregulated by miR-
140 in CRC cells.
miR-140 inhibits the migratory and invasive capacities
of CRC cells
Given the clinical significance of miR-140 in the CRC
specimens, we then assessed the impacts of miR-140 on
the cell migration and invasion using scratch-wound and
transwell chamber assays and determined the underlying
Fig. 1 miR-140 is decreased in CRC specimens. The qRT-PCR analysis
of miR-140 was performed in 60 paired human CRC and the matched
adjacent noncancerous tissues. Expression level of miR-140 was
normalized by the internal control RNU6B in each sample. *P < 0.05
Table 1 The relationship between miR-140 expression and
clinicopathological parameters in colorectal cancer
Characteristics No. of
cases






< 60 years 22 10 12
≥ 60 years 38 18 20
Gender 0.778
Male 33 16 17
Female 27 12 15
Tumor size 0.602
< 5 cm 23 12 11
≥ 5 cm 37 16 21
Stage 0.045*
I/II 28 1 27
III/IV 32 27 5
Differentiation 0.076
Well/moderate 24 13 11
Poor 36 15 21
Metastasis 0.031*
No 31 7 24
Yes 29 21 8
*P < 0.05
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mechanism. In order to eliminate the effect of cell prolif-
eration, CRC cells were cultured in the serum-free
medium when performing the scratch-wound assay. As
Fig. 3a showed, the gap was broader in the miR-140-
transfection cells compared with the negative controls
both in HCT116 and RKO cells, and the wound closure
was also significantly inhibited by silenced ADAMTS5
or IGFBP5. The cell migratory capacity as assessed by
transwell migratory assay (without matrigel) showed that
miR-140 overexpression significantly decreased migra-
tion of the HCT116 cells through the chamber com-
pared with the negative controls (55.2 ± 7.5 vs. 107.2 ±
8.5 or 112.3 ± 6.1, P < 0.05; Fig. 3b). Similarly, silenced
ADAMTS5 or IGFBP5 also reduced the migratory
HCT116 cells compared to the negative controls (50.6
± 2.3 or 47.9 ± 3.6 vs. 107.2 ± 8.5 or 112.3 ± 6.1, P < 0.05;
Fig. 3b). Similar results were also obtained in RKO cells
(Fig. 3b).
Transwell invasion assay (with matrigel) showed that
HCT116 cells with miR-140 overexpression penetrating
through the membrane were remarkably less than those
in the negative control groups (41.7 ± 4.5 vs. 83.2 ± 6.1
or 82.6 ± 7.9, P < 0.05; Fig. 3c), while silenced ADAMTS5
(32.9 ± 3.8) or IGFBP5 (35.8 ± 2.6) had a similar effect
with miR-140 overexpression (Fig. 3c). The results from
RKO cells were consistent with the data from HCT116
cells (Fig. 3c). Together, miR-140 inhibits the capacities
of migration and invasion of CRC cells in vitro, possibly
through targeting of ADAMTS5 and IGFBP5.
Knockdown of miR-140 promotes the migratory and
invasive capacities of CRC cells
So far we have assessed the significance of miR-140 in
the CRC migration and invasion using a gain-in ap-
proach. In order to further elucidate the impacts of miR-
140, we performed a series of knockdown experiments
Fig. 2 ADAMTS5 and IGFBP5 are downregulated by miR-140 in CRC cells. a The mRNAs of ADAMTS5 and IGFBP5 contain putative binding sites
of miR-140. b HCT116 and RKO cells were transfected with miR-140 mimic using oligofectamine. Oligofectamine alone (Control) and negative
miRNA (NC) were the negative controls. The relative expression of miR-140 was determined by qRT-PCR after normalization to the internal control,
RNU6B. *P < 0.05. c Protein expressions of ADAMTS5 and IGFBP5 were analyzed by Western blot. CRC cells transfected with siRNA specific against
ADAMTS5 (siADAMTS5) and IGFBP5 (siIGFBP5), respectively, were the positive control. The quantitative results of Western blot were analyzed by
Gel-Pro Analyzer 4.0 software, and GAPDH was used as a loading control. *P < 0.05. d ADAMTS5 and IGFBP5 mRNA levels were measured by
qRT-PCR and GAPDH was used as the internal control. *P < 0.05. e HCT116 and RKO cells were transfected with miR-140 inhibitor (Anti-miR-140)
using lipofectamine 2000. Lipofectamine 2000 (Control), scrambled miRNA inhibitor (Anti-NC) and co-transfection of miR-140 inhibitor and siRNA
against ADAMTS5 (140i + siADAMTS5) or IGFBP5 (140i + siIGFBP5) were the negative controls. ADAMTS5 and IGFBP5 proteins were quantified by
Western blot. *P < 0.05
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using miRNA inhibitors in HCT116 and RKO cells. As
shown in Fig. 3d and e, antagonizing the endogenous
miR-140 enhanced the CRC cell migratory potential com-
pared to the negative controls using scratch-wound and
transwell migration assays. Similarly, the cell invasion
impact caused by endogenous miR-140 was reversed by
knock down assay (Fig. 3f). These results are highly con-
sistent with those obtained from exogenous miR-140 over-
expression experiments. Thus, miR-140 impairs the
migratory and invasive capacities of CRC cells in vitro,
possibly via downregulating ADAMTS5 and IGFBP5.
ADAMTS5 and IGFBP5 are inversely correlated with the
expression of miR-140 and enhance the progression and
metastasis of CRC
Previously we confirmed that ADAMTS5 and IGFBP5
were downregulated by miR-140 in the CRC cell lines,
and miR-140 expression was decreased in the CRC spec-
imens as compared to the normal colorectal tissues. To
further prove the regulatory interaction of miR-140 and
ADAMTS5 and IGFBP5, we used qRT-PCR to measure
the mRNA levels of ADAMTS5 and IGFBP5 in the same
CRC cohort. The expressions of ADAMTS5 and IGFBP5
mRNA were dramatically increased in CRC specimens
compared with adjacent normal tissues (Fig. 4a; P < 0.05),
and the expression patterns were inversely correlated with
that of miR-140 (Fig. 4b). These data in the clinical speci-
mens further prove the negative regulatory interaction of
miR-140 and ADAMTS5 and IGFBP5 concluded from the
in vitro experiments.
We also performed immunohistochemistry to assess
the expressions and clinical significance of ADAMTS5
and IGFBP5 proteins in the CRC cohort. As Fig. 4c
showed, the positive percentages of ADAMTS5 and
IGFBP5 expressions were 74.33% and 68.33%, respect-
ively, in the primary CRC samples. When compared to
the adjacent normal tissues (19.71% or 21.34%), the dif-
ferences reached significance (both P < 0.05). These find-
ings are consistent with the ADAMTS5 and IGFBP5
mRNA expressions, indicating that ADAMTS5 and
IGFBP5 overexpression are related to the development
of CRC.
Next, we analyzed the relationship of ADAMTS5 and
IGFBP5 expression with the clinicopathological charac-
teristics of the CRC patients. The results showed that
overexpression of ADAMTS5 and IGFBP5 were posi-
tively correlated with the TNM stage and metastasis (all
P < 0.05; Table 2). No significant correlation was found
with the remaining parameters (Table 2). Taken together,
these results suggest that the expression of ADAMTS5
and IGFBP5 is positively correlated with the progression
and metastasis of CRC.
Fig. 3 miR-140 suppresses the migratory and invasive potentials of CRC cells. a, b and c CRC cells were first transfected with the miRNA mimics
or siRNAs. Cell migratory and invasive potentials were then determined by the scratch-wound assay and transwell chamber assays with or without
matrigel. d, e and f Similarly, scratch-wound assay and transwell assays with or without matrigel were used to determine the potential for migra-
tion and invasion in the miR-140 knockdown CRC cells. The representative pictures were chosen from three independent experiments. The cell
numbers passing through the filter are indicated as mean ± SD. *P < 0.05
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Discussion
The complications arising from metastasis become the
major causes of death from cancer. In this study, we re-
vealed a novel mechanism for the inhibition of miR-140
in the CRC progression through targeting ADAMTS5
and IGFBP5. Our interest in miR-140 was due to our
previous study that indicates its effects on CRC cell pro-
liferation and chemoresistance [13]. We reasoned that
miR-140 may influence CRC progression and be a key
regulator in CRC.
Firstly we observed a dramatic decrease in miR-140 in
the CRC samples as compared to the adjacent normal
tissues (Fig. 1). This is consistent with the results from
our previous study [13] and a recent study [21]. More
importantly, miR-140 downregulation was significantly
associated with advanced clinical stage and distant me-
tastasis of CRC (Table 1). In accordance with our results,
Zhai et al. [21] found a more progressive reduction in
miR-140 in the metastatic CRC tissues than in the pri-
mary tissues, and patients with high miR-140 expression
had a much longer survival time, further supporting the
inhibitory effect of miR-140 on the CRC metastasis.
miR-140 downregulation has also been verified in other
solid cancers including HCC, NSCLC, and esophageal
cancer [14–16], and miR-140 is negatively associated
with tumor stage and metastasis of HCC and NSCLC
Fig. 4 ADAMTS5 and IGFBP5 are inversely correlated with the expression of miR-140 and positively correlated with the tumor stage and metastasis of
CRC. a qRT-PCR analysis of ADAMTS5 and IGFBP5 expressions in 60 pairs of CRC and adjacent nontumorous tissues. b Correlation of ADAMTS5 and
IGFBP5 and miR-140 expression was analyzed by Spearman correlation test in CRC tissues. c Immunohistochemistry analysis of ADAMTS5
and IGFBP5 expressions in CRC tissues. 1, 2, 5 and 6: magnification × 20; and 3, 4, 7 and 8: magnification × 40; 1, 3, 5 and 7: primary sites
of tumor tissue; and 2, 4, 6 and 8: noncancerous region of CRC. Scale bar = 100 μm. The results of immunohistochemistry were evaluated
by the staining scores. *P < 0.05
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[14, 15]. The clinical relevance of miR-140 in these
tumor samples indicates that miR-140 might be a critical
regulator of cancer progression.
We next confirmed the inhibitory effects of miR-140
on the CRC cell migration and invasion in vitro (Fig. 3).
Several studies have shown that miR-140 participates in
the tumor invasion and metastasis through targeting
TGFBR1, FGF9, IGF1R, MMD, and Slug [14–16]. In the
current study, we confirmed that ADAMTS5 and
IGFBP5 are downregulated by miR-140 in the CRC cell
lines (Fig. 2). The inhibition of CRC cell migration and
invasion by miR-140 is achieved possibly due to the sup-
pression of ADAMTS5 or IGFBP5 (Fig. 3). Our clinical
observations also showed that miR-140 has inverse cor-
relation with ADAMTS5 or IGFBP5 (Fig. 4). Consistent
with this, Güllü et al. [23] reported that, immunohisto-
chemically, IGFBP5-negative breast cancer samples have
a significantly increased expression of miR-140. How-
ever, their results indicated that miR-140 is dramatically
increased in the breast cancer samples [23]. This di-
fferent role of the same miRNA may depend on the
types of cell and tissue, and time point [40]. A similar
phenomenon exists in the stem cell proliferation. miR-
140 inhibits breast or colorectal CSC survival and cancer
invasive phenotype via downregulation of SOX2/9 or
Smad2 [17–21], whereas, during embryonic bone devel-
opment, miR-140 drives chondrocyte cell proliferation
[8, 9] by targeting HDAC4 and the subsequent tran-
scription of Runx2 [9]. This realization provides a
captivating twist to the study of whole-organism func-
tional genomics [40].
The role of ADAMTS5 in cancer has recently been in-
vestigated. However, little is known about its function in
CRC. Kim et al. [41] reported that ADAMTS5 is highly
methylated in CRC compared to the adjacent normal
mucosa. On the contrary, our results showed that
ADAMTS5 overexpression in the CRC specimens is as-
sociated with the TNM stage and metastasis (Table 2).
Knockdown of ADAMTS5 can inhibit the CRC cell mi-
gration and invasion (Fig. 3). It is well known that malig-
nant tumors destroy the surrounding extracellular
matrix (ECM) before invading and metastasizing [42].
As a metalloproteinase, ADAMTS5 possibly promotes
the CRC invasion and metastasis through breaking down
the ECM, but further investigations are still required to
help explain the function and underlying mechanism of
ADAMTS5 in CRC.
Recent studies have demonstrated that IGFBP5
might be a useful biomarker for cancerous tissue and
metastasis [31–37], but it also shows the opposite ef-
fects depending on cancer cell type and expression
method [30, 43–46]. In colon cancer, a study using the
rat model revealed that IGFBP5 is one of the top up-
regulated genes [35]. In accordance with this, we found
that IGFBP5 serves as a cancer promoter based on our
findings in the clinical CRC cohort and CRC cell lines
(Figs. 3 and 4 and Table 2 ). Cell migration is a key
step in the tumor metastasis process. Vitronectin
(VN), a major ECM component, facilitates its function
in diverse cellular processes such as cell migration and
cell attachment through interactions with a number of
ligands [47]. IGFBP5 has been confirmed to exert a
stimulatory effect on cell migration when forming
complexes with IGFI and VN in skin keratinocytes and
MCF7 breast cancer cells [48, 49]. Furthermore,
Yasuoka et al. [50] suggested that IGFBP5 induces cell
migration via MAPK-dependent and IGF-I-
independent mechanisms.
Conclusion
In summary, we experimentally prove that miR-140 in-
hibits CRC cell migration and invasion upon downregu-
lating ADAMTS5 and IGFBP5. ADAMTS5 and IGFBP5
are overexpressed in the CRC specimens and are in-
versely correlated with the levels of miR-140. miR-140
downregulation and ADAMTS5 and IGFBP5 overex-
pression contribute to the TNM stage and metastasis of
CRC. miR-140 might be a key regulator in CRC progres-
sion and metastasis and a potential therapeutic candi-
date for the treatment of CRC.
Table 2 Correlation between ADAMTS5 and IGFBP5 expression
and clinicopathological characteristics in colorectal cancer
Characteristic No. of
cases
ADAMTS5 P value IGFBP5 P value
(+) (–) (+) (–)
Age 0.467 0.378
< 60 years 22 14 8 16 6
≥ 60 years 38 18 20 28 10
Gender 0.564 0.867
Male 33 18 15 27 6
Female 27 14 13 17 10
Tumor size 0.745 0.675
< 5 cm 23 13 10 15 8
≥ 5 cm 37 19 18 29 8
Stage 0.041* 0.037*
I/II 28 3 25 4 24
III/IV 32 29 3 28 4
Differentiation 0.896
Well/moderate 24 15 9 18 6
Poor 36 17 19 26 10
Metastasis 0.027* 0.021*
No 31 5 26 4 27
Yes 29 27 2 26 3
*P < 0.05
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